Concord Biotech Limited (CONCORDBIO.NS)
INR 2147.65
(-1.18%)
INR 2147.65
(-1.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.65 Billion INR | 23.16% |
| 2022 | 3.83 Billion INR | 29.44% |
| 2021 | 2.97 Billion INR | -12.08% |
| 2020 | 3.41 Billion INR | 56.23% |
| 2019 | 2.14 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 929.4 Million INR | -36.88% |
| 2023 Q2 | 1.23 Billion INR | 45.99% |
| 2023 Q4 | 1.42 Billion INR | 22.0% |
| 2023 Q3 | 1.17 Billion INR | -5.41% |
| 2023 FY | - INR | 23.16% |
| 2023 Q1 | 848.3 Million INR | -39.08% |
| 2022 Q3 | 1.19 Billion INR | 217.02% |
| 2022 FY | - INR | 29.44% |
| 2022 Q4 | 1.39 Billion INR | 16.8% |
| 2022 Q2 | 376.06 Million INR | 0.0% |
| 2021 FY | - INR | -12.08% |
| 2020 FY | - INR | 56.23% |
| 2019 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biocon Limited | 41.52 Billion INR | 88.78% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | -103.251% |
| Dishman Carbogen Amcis Limited | 3.07 Billion INR | -51.674% |
| Jubilant Ingrevia Limited | 4.56 Billion INR | -2.079% |
| Lyka Labs Limited | 167.58 Million INR | -2680.082% |
| Panacea Biotec Limited | -47.58 Million INR | 9892.165% |
| Piramal Pharma Limited | 13.05 Billion INR | 64.313% |
| SMS Lifesciences India Limited | 349.41 Million INR | -1233.423% |
| Supriya Lifescience Limited | 1.83 Billion INR | -153.797% |
| Syngene International Limited | 10.84 Billion INR | 57.047% |
| TAKE Solutions Limited | -1.05 Billion INR | 543.37% |
| Zota Health Care Limited | 82.07 Million INR | -5576.79% |